Table 2.
Tenofovir pharmacokinetic parameters measured on days 3 and 14 of the study during treatment with saquinavir/ritonavir (SQV/RTV)
| Parameter | Day 3 SQV/RTV 1000/100 mg twice daily plus TDF 300 mg once daily | Day 14 SQV/RTV 1000/100 mg twice daily plus TDF 300 mg once daily |
|---|---|---|
| AUC (ng ml−1 h) | ||
| Geometric mean (95% Cl) | 2701 (2333–3423) | 3120 (2739–3875) |
| CV (%) | 40 | 37 |
| Cmax (ng ml−1) | ||
| Geometric mean (95% Cl) | 271 (235–351) | 292 (253–369) |
| CV (%) | 42 | 39 |
| Ctrough (ng ml−1) | ||
| Geometric mean (95% Cl) | 55 (49–79) | 69 (59–91) |
| CV (%) | 50 | 45 |
| t½ (h) | ||
| Geometric mean (95% Cl) | 14.9 (11.7–20.8) | 13.4 (12.2–15.4) |
| CV (%) | 54 | 23 |
TDF = tenofovir diproxil fumarate; AUC = area under the concentration vs. time curve; Cmax = highest observed plasma concentration; Ctrough = trough concentration at 12 h; t½ = apparent terminal half-life; CV = coefficient of variation.